Background : Type 1 diabetes is associated with an increased risk of fractures. The mechanisms accounting for this bone fragility are not yet fully understood. The lower bone mineral density (BMD) observed in individuals with type 1 diabetes cannot solely explain the higher fracture incidence. Bone microarchitecture defects significantly contribute to bone fragility. Few studies assessed spine fractures in type 1 diabetes. This cross-sectional multicenter case-control study aims (1) to evaluate the prevalence of asymptomatic vertebral fractures in individuals with type 1 diabetes in comparison to age- and sex-matched healthy controls; (2) to compare individuals with diabetes with vertebral fractures and those without vertebral fracture using clinical, biochemical and radiological parameters.
Study Type
OBSERVATIONAL
Enrollment
192
The investigators perform the following clinical tests: vibration threshold test, monofilament test, and height, weight and waist circumference measurement in every participant.
The investigators perform the following clinical tests: height, weight and waist circumference measurement in every participant.
The investigators perform blood and urine tests in every participant.
The investigators perform a dual energy x-ray absorptiometry (DXA scan or osteodensitometry) in every participant.
The investigators perform a skin advanced glycation end products (AGEs) measurement with the AGE Reader machine in every participant.
Institut de recherches cliniques de Montréal (IRCM)
Montreal, Quebec, Canada
Centre de recherche du CHU de Québec - Université Laval
Québec, Canada
Vertebral fracture detected with VFA
Vertebral Fracture Assessment (VFA) software of dual-energy X-ray absorptiometry (DXA scan) is used to identify vertebral fractures. If there is evidence of a vertebral fracture on VFA, a lateral and anteroposterior spine X-ray will be obtained to confirm the VFA results.
Time frame: Baseline
Areal bone mineral density of the spine in g/cm2
Measured by DXA scan
Time frame: Baseline
Areal bone mineral density of the spine, T-score
Measured by DXA scan
Time frame: Baseline
Areal bone mineral density of the spine, Z-score
Measured by DXA scan
Time frame: Baseline
Areal bone mineral density of proximal femur in g/cm2
Measured by DXA scan
Time frame: Baseline
Areal bone mineral density of proximal femur, T-score
Measured by DXA scan
Time frame: Baseline
Areal bone mineral density of proximal femur, Z-score
Measured by DXA scan
Time frame: Baseline
Areal bone mineral density of total hip in g/cm2
Measured by DXA scan
Time frame: Baseline
Areal bone mineral density of total hip, T-score
Measured by DXA scan
Time frame: Baseline
Areal bone mineral density of total hip, Z-score
Measured by DXA scan
Time frame: Baseline
Areal bone mineral density of distal radius in g/cm2
Measured by DXA scan
Time frame: Baseline
Areal bone mineral density of distal radius, T-score
Measured by DXA scan
Time frame: Baseline
Areal bone mineral density of distal radius, Z-score
Measured by DXA scan
Time frame: Baseline
Lean mass (arm, leg, trunk, android, gynoid and total)
Body composition measured by DXA scan
Time frame: Baseline
Fat mass (arm, leg, trunk, android, gynoid and total)
Body composition measured by DXA scan
Time frame: Baseline
Skin AGE measurement
Measured by AGE Reader
Time frame: Baseline
C-telopeptide
Bone turnover marker (serum)
Time frame: Baseline
Sclerostin
Bone turnover marker (serum)
Time frame: Baseline
Osteocalcin
Bone turnover marker (serum)
Time frame: Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.